• KOL
    • KOLs Community
    • Cytoreductive
    • Cytoreductive Surgery
    • Paul Hendrick Sugarbaker
    • Paul Hendrick Sugarbaker

      Paul Hendrick Sugarbaker

      Washington Cancer Institute, Program in Peritoneal Surface Malignancy, Washington, District of Columbia, USA | Program in Peritoneal Surface Malignancy, Washington Cancer ...

       

       

      KOL Resume for Paul Hendrick Sugarbaker

      Year
      2022

      Washington Cancer Institute, Program in Peritoneal Surface Malignancy, Washington, District of Columbia, USA

      2021

      Program in Peritoneal Surface Malignancy, Washington Cancer Institute, Washington, DC, USA; Sugarbaker Oncology 3629 Fulton St. NW, Washington, DC, 20007, USA. Electronic address:

      MedStar Washington Hospital Center, Washington, DC, USA.

      Washington Cancer Institute, Washington Hospital Center, Washington, DC

      2020

      Center for Gastrointestinal Malignancies, Program in Peritoneal Surface Oncology, MedStar Washington Hospital Center, Washington, DC 20010, United States.,

      Program in Peritoneal Surface Oncology, Washington Cancer Institute, Washington, DC, USA.

      2019

      Department of Surgery, Washington Hospital Center, Washington DC, USA

      Center for Gastrointestinal Malignancies, MedStar Washington Hospital Center, Washington, District of Columbia

      2018

      MedStar Washington Hospital Center, Peritoneal Surface Oncology Unit, Washington, DC

      Department of Surgical Oncology, Washington Hospital Center, Washington, United States

      2017

      Center for Gastrointestinal Malignancies, MedStar Washington Hospital Center, 106 Irving St., NW, Suite 3900, Washington, 20010, DC, USA

      2016

      Washington Cancer Institute, MedStar Washington Hospital Center, Washington, DC, USA

      Lieselotte Lemoine, Kurt Van der Speeten, Department of Surgical Oncology, Ziekenhuis Oost-Limburg, 3600 Genk, Belgium

      2015

      Washington Cancer Institute, MedStar Washington Hospital Center, Washington, DC

      2014

      1 NPO HIPEC ISTANBUL, Akkavak Sokak No: 4/2 Nisantasi, Istanbul 34365, Turkey ; 2 Ethica Incirli Hospital, Bakirkoy, Istanbul 34144, Turkey ; 3 NPO to support Peritoneal Dissemination Treatment, 1-26, Harukimotomachi, Kishiwada City, Osaka 596-8522, Japan ; 4 Department of General Surgery, Kusatsu General Hospital, Yabase 1660, Kusatsu, Japan ; 5 Department of General Surgery, Kishiwada Tokushukai Hospital, 4-27-1 Kamori-Cho, Kishiwada City, Osaka 596-8522, Japan ; 6 Department of Peritoneal Surface Malignancy, Bon Secours Cancer Institute, Richmond VA 23226, USA ; 7 Deparment of General Surgery, Yonsei University College of Medicine, Seoul, South Korea ; 8 Center for Gastrointestinal Malignancies, Program in Peritoneal Surface Oncology, MedStar Washington Hospital Center, NW, POB North Tower 3900 Washington, DC 20010, USA.

      Program in Peritoneal Surface Malignancy, MedStar Washington Hospital Center, Washington, DC USA

      2013

      Washington Cancer Institute, Washington Hospital Center, Washington, 20010 DC, USA

      2012

      Washington Cancer Institute, Program in Peritoneal Surface Malignancy, Washington, DC 20010, USA.

      2011

      Washington Cancer Institute, Washington Hospital Center, 106 Irving Street, NW, Suite 3900, Washington, DC 20010, USA

       

       

      Paul Hendrick Sugarbaker: Influence Statistics

      Sample of concepts for which Paul Hendrick Sugarbaker is among the top experts in the world.
      Concept World rank
      pmcas adenocarcinoid #1
      loss peritoneal implants #1
      disease peritoneal cancer #1
      prognostic assessment features #1
      3 additional cycles #1
      tests factual humans #1
      hepatic bridge tunnel #1
      carcinomatosis colon #1
      intraperitoneal 5fu patients #1
      secondlook surgery disease #1
      experience cytoreductive surgery #1
      cancer mmc #1
      aged appendiceal neoplasms #1
      hiic epic #1
      adequate management plan #1
      origin treated #1
      surgery perioperative #1
      intravenous cisplatin crs #1
      small bowel omentum #1
      primary immune splenocytes #1
      abdomen peritoneal surfaces #1
      extremity sarcomas patterns #1
      psoas crs #1
      doxorubicin lymph nodes #1
      program peritoneal malignancy #1
      containment malignancy #1
      dianeal 34 paclitaxel #1
      washington cancer institute #1
      recurrent intraabdominal sarcoma #1
      structures peritoneal metastases #1
      pmcas patients #1
      condition hiic #1
      415 degrees cytotoxicity #1
      doxorubicin peritoneal space #1
      revised prognostic indicators #1
      complete pelvic peritonectomy #1
      long term nipeclt #1
      malignancy appendiceal #1
      allograft primary recipient #1
      contracted peritoneal space #1
      mortality cytoreductive surgery #1
      ifosfamide 4hydroxyifosfamide #1
      appendicectomy hemicolectomy #1
      progression malignant process #1
      peritoneal progression #1
      hipec india #1
      98 patients #1
      pancreas cancer paclitaxel #1
      pmcaa appendix #1
      crs ulms #1

       

      Prominent publications by Paul Hendrick Sugarbaker

      KOL-Index: 19981

      Pseudomyxoma peritonei (PMP) is a poorly understood condition characterized by the accumulation of abundant mucinous material within the peritoneal cavity and associated with a mucinous tumor of the gastrointestinal tract or ovaries. Recently there has been considerable debate over the primary site of origin of the tumor associated with PMP in women. Some investigators have proposed a primary site in the ovaries, whereas others favor the gastrointestinal tract or the peritoneum. Another ...

      Known for Ovarian Mucinous | Low Malignant Potential | Pseudomyxoma Peritonei | Clinicopathologic Analysis | 30 Cases
      KOL-Index: 17612

      BACKGROUND: Pseudomyxoma peritonei (PMP) is a poorly understood condition characterized by disseminated intraperitoneal mucinous tumors, often with mucinous ascites. The term PMP has been applied historically as a pathologic diagnostic term to both benign and malignant mucinous neoplasms that produce abundant extracellular mucin, resulting in a variable and poorly predictable prognosis. A recent study reported a pathologic classification that separated patients into prognostically ...

      Known for Peritoneal Mucinous | Pmca Patients | Pseudomyxoma Peritonei | Abundant Extracellular Mucin | Year Survival
      KOL-Index: 16287

      BACKGROUND: There is no consensus on diagnosis and management of ASBO. Initial conservative management is usually safe, however proper timing for discontinuing non operative treatment is still controversial. Open surgery or laparoscopy are used without standardized indications.

      METHODS: A panel of 13 international experts with interest and background in ASBO and peritoneal diseases, participated in a consensus conference during the 1st International Congress of the World Society of ...

      Known for Emergency Surgery | Bologna Guidelines | Management Asbo | Small Bowel | Signs Strangulation
      KOL-Index: 15629

      BACKGROUND: In 2013 Guidelines on diagnosis and management of ASBO have been revised and updated by the WSES Working Group on ASBO to develop current evidence-based algorithms and focus indications and safety of conservative treatment, timing of surgery and indications for laparoscopy.

      RECOMMENDATIONS: In absence of signs of strangulation and history of persistent vomiting or combined CT-scan signs (free fluid, mesenteric edema, small-bowel feces sign, devascularization) patients with ...

      Known for Surgery Asbo | Diagnosis Management | Small Bowel | Based Guidelines | Signs Strangulation
      KOL-Index: 15421

      PURPOSE: The initial dissemination of colon cancer occurs through three routes: the lymphatics, the portal blood, and the peritoneal surfaces. Although lymphatic and hematogenous metastases indicate an aggressive disease process, it is possible that dissemination to peritoneal surfaces may be only superficial contamination of the parietal and visceral peritoneum that may be treatable for cure. Unfortunately, surgery may have an adverse impact on peritoneal surface dissemination. Surgical ...

      Known for Peritoneal Carcinomatosis | Colon Cancer | Peritonectomy Procedures | Definitive Treatment | Year Survival
      KOL-Index: 13649

      Introduction: In the past, peritoneal carcinomatosis, regardless of primary tumor type, has always been a lethal condition. Recently, special treatments using cytoreductive surgery with peritonectomy procedures combined with perioperative intraperitoneal chemotherapy have resulted in long-term survival. Appendiceal malignancy with a low incidence of liver and lymph node metastases may be especially appropriate for these aggressive local regional treatments.Methods: All patients treated ...

      Known for Appendiceal Malignancy | Peritoneal Surface | Patients Adenomucinosis | Complete Cytoreduction | 5year Survival
      KOL-Index: 13513

      PURPOSE: There is no standard treatment for peritoneal metastases (PM) from gastric cancer (GC). The aim of this review is to evaluate the clinical trials on cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC) for GC PM.

      MATERIALS AND METHODS: The published clinical trials on CRS + HIPEC for GC PM are critically evaluated, and survival and safety are the primary endpoints. In addition, the registered ongoing clinical trials are summarised.

      RESULTS: The ...

      Known for Crs Hipec Crs | Peritoneal Metastases | Gastric Cancer | Hipec Survival | Cytoreductive Surgery
      KOL-Index: 13386

      PURPOSE: The purpose of this study was to report the pharmacokinetics of heated intraoperative intraperitoneal mitomycin C (MMC) and to analyze the impact of heat, extent of peritoneal resections, and effect of intraoperative hyperthermic chemotherapy on the pharmacological properties of the peritoneal plasma barrier.

      METHODS: Sixty patients with peritoneal carcinomatosis were included in a phase I/II study combining cytoreductive surgery with 2 h of heated intraperitoneal mitomycin C in ...

      Known for Intraoperative Intraperitoneal | Pharmacokinetic Studies | Early Postoperative | Antineoplastic Antimetabolites | Induced Infusions
      KOL-Index: 13290

      BACKGROUND: Hyperthermia enhances the cytotoxicity of some chemotherapeutic agents and recent studies suggest that docetaxel may show improved response at elevated temperatures. Factors that may modify the thermal enhancement of docetaxel were studied to optimize its clinical use with hyperthermia.

      METHODS: The tumor studied was an early-generation isotransplant of a spontaneous C3Hf/Sed mouse fibrosarcoma, Fsa-II. All studies were approved by the Animal Care and Use Committee. Docetaxel ...

      Known for Thermal Enhancement | Docetaxel Administration | Hyperthermia Treatment | Antineoplastic Agents | Induced Injections
      KOL-Index: 12591

      BackgroundThe purpose of this systematic review and meta-analysis was to determine the effectiveness and safety of adjuvant intraperitoneal chemotherapy for patients with locally advanced resectable gastric cancer.MethodsStudies eligible for this systematic review included those in which patients with gastric cancer were randomly assigned to receive surgery combined with intraperitoneal chemotherapy versus surgery without intraperitoneal chemotherapy. There were no language restrictions. ...

      Known for Intraperitoneal Chemotherapy | Randomized Controlled Trials | Gastric Cancer | Induced Injections | Systematic Review Metaanalysis
      KOL-Index: 12549

      PURPOSE: The three principal studies dedicated to the natural history of peritoneal carcinomatosis (PC) from colorectal cancer consistently showed median survival ranging between 6 and 8 months. New approaches combining cytoreductive surgery and perioperative intraperitoneal chemotherapy suggest improved survival.

      PATIENTS AND METHODS: A retrospective multicenter study was performed to evaluate the international experience with this combined treatment and to identify the principal ...

      Known for Cytoreductive Surgery | Perioperative Intraperitoneal | Colorectal Cancer | Peritoneal Carcinomatosis | Combined Treatment Patients
      KOL-Index: 12520

      Pseudomyxoma peritonei (PMP) is a complex disease with unique biological behavior that usually arises from appendiceal mucinous neoplasia. The classification of PMP and its primary appendiceal neoplasia is contentious, and an international modified Delphi consensus process was instigated to address terminology and definitions. A classification of mucinous appendiceal neoplasia was developed, and it was agreed that "mucinous adenocarcinoma" should be reserved for lesions with infiltrative ...

      Known for Pseudomyxoma Peritonei Pmp | Pathologic Reporting | Mucinous Appendiceal | Infiltrative Invasion | Peritoneal Neoplasms
      KOL-Index: 12290

      PURPOSE: Pseudomyxoma peritonei (PMP) originating from an appendiceal mucinous neoplasm remains a biologically heterogeneous disease. The purpose of our study was to evaluate outcome and long-term survival after cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) consolidated through an international registry study.

      PATIENTS AND METHODS: A retrospective multi-institutional registry was established through collaborative efforts of participating units ...

      Known for Cytoreductive Surgery | Pseudomyxoma Peritonei | Appendiceal Origin | Intraperitoneal Chemotherapy | Term Outcome
      KOL-Index: 11811

      Peritoneal carcinomatosis, regardless of primary tumour type, has always been a lethal condition. Recently special treatments using cytoreductive surgery with peritonectomy procedures combined with peri-operative intraperitoneal chemotherapy have resulted in long-term survival. Pseudomyxoma peritonei may be especially appropriate for these aggressive local regional treatments. All patients treated prior to 1999 are presented; patients left with gross residual disease after surgery were ...

      Known for Intraperitoneal Chemotherapy | Pseudomyxoma Peritonei | Cytoreductive Surgery | Multivariate Analysis | Complete Cytoreduction

      Key People For Cytoreductive Surgery

      Top KOLs in the world
      #1
      Paul Hendrick Sugarbaker
      cytoreductive surgery peritoneal carcinomatosis colorectal cancer
      #2
      Olivier J Glehen
      cytoreductive surgery peritoneal carcinomatosis gastric cancer
      #3
      Dominique M Elias
      peritoneal carcinomatosis cytoreductive surgery liver metastases
      #4
      Francois‐Noel Gilly
      cytoreductive surgery peritoneal carcinomatosis pseudomyxoma peritonei
      #5
      Marcello Deraco
      cytoreductive surgery peritoneal mesothelioma crs hipec
      #6
      Edward Allen Levine
      cytoreductive surgery crs hipec breast cancer

      Paul Hendrick Sugarbaker:Expert Impact

      Concepts for whichPaul Hendrick Sugarbakerhas direct influence:Cytoreductive surgery,  Peritoneal carcinomatosis,  Intraperitoneal chemotherapy,  Peritoneal metastases,  Colorectal cancer,  Pseudomyxoma peritonei,  Peritoneal mesothelioma,  Gastric cancer.

      Paul Hendrick Sugarbaker:KOL impact

      Concepts related to the work of other authors for whichfor which Paul Hendrick Sugarbaker has influence:Cytoreductive surgery,  Colorectal cancer,  Peritoneal carcinomatosis,  Pseudomyxoma peritonei,  Crs hipec,  Liver metastases,  Adjuvant chemotherapy.


       

      Tools

      Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile


      Washington Cancer Institute, Program in Peritoneal Surface Malignancy, Washington, District of Columbia, USA | Program in Peritoneal Surface Malignancy, Washington Cancer Institute, Washington, District of Columbia, USA. | Washington Cancer Institute

    Download on the App StoreGet it on Google Play

    Copyright © 2023 - KOL means Key Opinion Leaders .

    KOL does not provide medical advice, diagnosis or treatment.